NCT05886088View on ClinicalTrials.gov

Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

597

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

January 31, 2027

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

LID104

Experimental

DRUG

Dapagliflozin

Active comparator

DRUG

Linagliptin

Active comparator

Trial Locations (1)

Unknown

Investigational site, Hortolândia

Sponsors

Lead Sponsor

All Listed Sponsors

lead

EMS

INDUSTRY

NCT05886088 - Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus | Biotech Hunter | Biotech Hunter